17530(AP) PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicant:** Tatton et al. )
**Serial No.:** 10/680,996 )
**Customer No.:** 051957 )
**Conf. No.:** 6653 )
**Filed:** October 7, 2003 )
)
**For:** Methods for the Treatment of )
Neurodegeneration )
**Examiner:** D.R. Claytor )
_____ )

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Alexandria, VA 22313-1450

Dear Sir:

Applicant herewith submits forms PTO 1449 for consideration by the Examiner, consistent with the provisions of 37 CFR §§ 1.97 and 1.98. By submitting this Information Disclosure Statement, Applicant makes no admission that any item listed thereupon is material to the patentablility of the invention claimed in the above-entitled patent application. Further, Applicant makes no assertion hereby that a search was conducted, or if conducted, that any search was thorough.

Applicant respectfully requests that the Examiner indicate consideration of the presently cited references by returning the enclosed Form 1449 bearing the Examiner's initials and the date considered.

No fee or certification is thought to be required, pursuant to 37 CFR §1.97(b). If Applicant is in error in this regard, please use Deposit Account 01-0885 for payment of any fee that may be due.

Respectfully submitted,

/Joel B. German/

Date: July 24, 2008

Joel B. German
Reg. No. 48,676
ALLERGAN, INC.- T2-7H
2525 Dupont Drive
Irvine, CA 92612
Tel: 714-246-4920 Fax: 714-246-4249